🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating worldwide, with data suggesting over 82 million infections per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, also known as a brand name, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per results published in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which uses an injection and a pill. The research involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced optimism. The availability of a single-dose, oral treatment like this is hailed as a "game-changer" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea around the world.